Eliminating Uncertainty in Coronary Artery Disease

Informazioni relative al progetto

EU-CAD

ID dell’accordo di sovvenzione: 960899

DOI

10.3030/960899

Progetto chiuso

Data della firma CE 19 Agosto 2020

Data di avvio 1 Agosto 2020

Data di completamento 31 Luglio 2022

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale

€ 3 572 775,00

Contributo UE

€ 2 500 000,00

Coordinato da

MEDTRACE PHARMA A/S
Denmark

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Demonstrators, pilots, prototypes (1)

2.2 Code and Infrastructure Validation

Based on Deliverable 2.2. the new aQuant code and infrastructure will be tested at selected hospitals in Europe and validated according to EU regulatory standards as well as operational specifications defined in deliverable 2.1.

Documents, reports (2)

3.2 Regulatory Approval EU

Founded on deliverable 31 the subsequent focus is to apply for and achieve regulatory approval for the MedTrace solution in the EU in the form a CEmark as medical device of the software and the medical device part of the hardware

3.1 Clinical Study EU

"In order to approve the MedTrace solution as medical device, the company needs to carry out a minor clinical study using 15O-water in cardiac patients to prove safety and efficacy. Part of this study is to purchase already existing data from Amsterdam University Medical Centers from a recent similar clinical trial. In parallel the clinical study will be prepared (study protocol, site recruitment, clinical trial agreements and patient recruitment) End deliverable is ""last patient scanned""."

Pubblicazioni

Other (3)

Initial Experience with routine 15O-water cardiac PET workflow

Autori: Susanne Hansen, Jeppe Madsen, Shakti Nicolai Johansen, Charlotte Jensen, Lone Winkler, Lars Gormsen and Lars Tolbod, ,
Pubblicato in: Journal of Nuclear Medicine, Numero May 2021, 62 (supplement 1), 2021, Pagina/e 3001, ISSN 2047-2412
Editore: SNM

Cardiac viability PET using combined parametric 15O-water blood flow/18F-FDG metabolism compares well with 82Rb/18F-FDG

Autori: Mette Kjaerulff, Simon Madsen, Kirsten Bouchelouche, Lars Gormsen and Lars Tolbod
Pubblicato in: Journal of Nuclear Medicine, Numero May 2021, 62 (supplement 1), 2021, Pagina/e 1632
Editore: SNMMI

Routine clinical use of 15O-water cardiac PET: Initial experience with a novel automated solution

Autori: LP Tolbod, LC Gormsen
Pubblicato in: European Heart Journal - Cardiovascular Imaging, Numero Volume 22, Numero Supplement_3, June 2021, 2021
Editore: European Society of Cardiology
DOI: 10.1093/ehjci/jeab111.029